AbbVie on Twitter: "Tom Hudson joined AbbVie to help bring innovative treatments to patients faster. Learn more about his vision for the future of cancer treatment via @CancerResearch: https://t.co/XdfWDnDzpd https://t.co/QM87UDuA0j" / Twitter
A collaboration between the IRIC and AbbVie facilitated by IRICoR featuring Dr. Tom Hudson - YouTube
Strategic Advisory Board
Dr. Thomas J. Hudson Net Worth (2022) | wallmine
AbbVie Careers - Tom Hudson has six sisters, including a twin sister, who were all drawn to science careers. “There wasn't any pressure to be in this field,” Tom says. “My dad
AbbVie's risankizumab improves symptoms of psoriatic arthritis in trials
AbbVie: ChemBeads, Improving Artificial Intelligence Through Human Ingenuity
Thomas Hudson - DIA 2020 Virtual Global Annual Meeting
70+ "Hudson, Ms" profiles | LinkedIn
Thomas Hudson's email & phone | AbbVie's Senior Vice Research and Development and Chief Scientific Officer email
AbbVie and Regenxbio ink $1.75 billion eye care collaboration
AbbVie signs immunotherapy deal with I-Mab worth $2bn - Pharmaceutical Technology
AbbVie Helps to Advance Gene Therapy for Chronic Retinal Diseases
Thomas Hudson, M.D - Our R&D Leaders - Our Science | AbbVie
AbbVie shares new Rinvoq data involving patients with psoriatic arthritis - Drug Discovery and Development
AbbVie on Twitter: "#DYK we partner with others to give science an edge against tough diseases like #COVID19 and #cancer? This lets us “remain creative, nimble and innovative as we develop therapies
AbbVie Makes Large Investment in Regenxbio's Gene Therapy for Retinal Diseases - Eyewire+
Partner Spotlight: Thomas Hudson - Cancer Research Institute (CRI)
John Sansone - Sales Representative - AbbVie | LinkedIn
Our R&D Leaders - Our Science | AbbVie
Major cash injection for Alphabet and AbbVie's R&D program
Eyeing its post-Humira future, AbbVie angles for broader Rinvoq use in U.S., Europe | FiercePharma
